Novo Nordisk partners with Anthropic to speed drug development using Claude Science
Polymarket · x · 2026-09-16
Polymarket gives only a 3% chance of FDA approving Eli Lilly's Retatrutide this year ($586K volume). The triple-agonist peptide drug is in trials for obesity, fatty liver, type-2 diabetes, and more.
In the same thread, Polymarket relayed breaking news: Ozempic maker Novo Nordisk is partnering with Anthropic to accelerate drug development using Claude Science.
Related event: Novo Nordisk Partners with Anthropic to Speed Up Drug Development(2 posts)→
More from Companies & People
- OpenAI's OpenRouter share jumps from 20% to 50% vs Anthropic in two months — GavinSBaker · 2026-09-16
- How Mars' 12-person data science team powers AI across a $50B org — rschmelzer · 2026-09-16
- CPAL 2027 heads to Tokyo: small conference on parsimony and learning — YiMaTweets · 2026-09-16
- OpenAI expands ChatGPT ads with Sponsored Agents — petrusenko_max · 2026-09-16
- The CIO in 2030: humans bid against agents, IT runs as a market, not an org chart — brucemacv · 2026-09-16
- Startups push back as Anthropic and OpenAI champion safety coordination that may squeeze smaller rivals — nmasc_ · 2026-09-16